European Funds

MetAron – Development of Diabetes Treatment support products based on natural extracts rich
in polyphenols compounds.


Project goals: The overarching goal of the project is to launch new, previously absent products based on natural extracts rich in polyphenol compounds, including from chokeberry, evening primrose and other polyphenol-rich plants whose mechanism of action will be support for metformin treatment, including cytoprotective effects – reducing the symptoms of intolerance to currently used drugs.

An additional aspect will be support for the treatment of pre-diabetes, which is a serious health condition where blood sugar is higher than normal but not high enough to be diagnosed with diabetes. Prediabetes increases the risk of developing metabolic disease: type 2 diabetes, heart disease and stroke.

 Planned effects:

As a result of the project, a product will be obtained that is a new, unique mixture of various extracts with a high content of polyphenols, not yet available on the market. An appropriate product formulation will also be developed to increase the overall bioavailability of polyphenolic compounds and a formulation to increase the activity of the preparation mainly in the intestines.

 Project value: PLN 3,948,188.70
Co-financing value: PLN 2 960 982,92
Project implementation period: 2019 – 2023

 Project co-financed by the European Union from the European Regional Development Fund under the Intelligent Development Operational Program.

Project implemented as part of the National Center for Research and Development competition: Fast Track.

Beneficiary: AronPharma Limited company

European Funds

OncoAron – Innovative polyphenolic preparations obtained from berries used in the prevention and  minimization  of  chemotherapy  and radi o therapy-induced  side effects.



Project goals: launch of new products based on berry fruit extracts, in particular from chokeberry, which will exhibit cytoprotective properties and reduce the undesirable effects of chemo- and radiation therapy without causing side effects resulting from their use.

Planned effects: development and obtainment of new mixture of various extracts (including chokeberry extrtact) with a high anthocyanin content (above 20%) and polyphenols (above 45%) not yet available on the market.

Project value: PLN 4 907 693,35

Co-financing value: PLN 3 214 109,89

Project implementation period: 2020 – 2023

Beneficiary: AronPharma Limited company